相关实验视频
Updated: Jun 5, 2025
06:17
Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
24.1K
工程化髓质前体在小鼠中分化为骨质细胞,并重新吸收异型骨化
Cameron Rementer1, Apichai Yavirach2,3, Worakanya Buranaphatthana2,4
1Department of Bioengineering, School of Medicine, University of Washington, Seattle, WA, United States.
Frontiers in bioengineering and biotechnology
|December 9, 2024
概括
基因工程骨质细胞 (OCs) 在体内有效治疗异型骨化 (HO). 这种新的细胞疗法方法显示出对管理HO的承诺,HO是一种导致疼痛和有限移动性的疾病.
科学领域:
- 再生医学是一种再生医学.
- 细胞疗法细胞疗法
- 整形外科 整形外科 整形外科
背景情况:
- 异型骨化 (HO) 是创伤后的一种使人虚弱的疾病,导致疼痛和运动能力下降.
- 目前对HO的治疗方法有限,往往导致并发症和高复发率.
- 骨质结晶体 (OCs) 对于骨的再吸收至关重要,是HO的潜在治疗点.
研究的目的:
- 调查基因工程骨质细胞 (OCs) 作为治疗异型骨化 (HO) 的新型细胞疗法的疗效.
主要方法:
- 工程化骨髓体前体 (iRANK细胞) 通过使用化学诱导二元化 (CID) 分化为OCs.
- 这些工程化OCs的吸收能力在体外评估.
- 在体内评估了iRANK细胞治疗对BMP-2诱导的HO病变的治疗效果.
主要成果:
- 工程化OCs在体外证明了矿化组织的再吸收.
- 用iRANK细胞和CID治疗显著回归已建立的HO病变 in vivo.
- 接受治疗的OCs证实了与交付的iRANK细胞的分化,表达了相关标记物 (TRAP+,MMP9+,GFP+).
结论:
- 经过基因工程的骨髓体前体可以分化为功能性OCs,能够在体内重新吸收HO.
- 工程化OCs的细胞输送代表了异型骨化的一种有前途的治疗策略.
- 这种方法为改善HO患者治疗结果提供了潜在的新途径.
相关概念视频
01:31Osteoclasts in Bone Remodeling
2.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K
01:40Bone Remodeling
38.1K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.1K